An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Active registration or continuous enrolment for at least 12 months in 1 of the selected data sources before the index date
No recorded prescription or dispensing of any medication in the class during the 12 months before the index date
Age 18 years or older as of the index date
Diagnosis of T2D on or before the index date
Diagnosis of CKD on or before the index date
You may not be if
Type 1 diabetes identified by appropriate algorithms in each participating data source
Kidney cancer on or before the index date
Kidney failure
\-- Maintenance dialysis on or before the index date
Kidney transplantation on or before the index date
Clareo Health | An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
